Engineering Cures for Autoimmune Diseases.

Blue shape

Tr1X is developing a novel class of regulatory T cell-based products to cure autoimmune and inflammatory diseases and transform patient lives.

About Us

Company Overview

Tr1X (pr. “Trix”) - developing  therapies to restore homeostasis.

Our novel regulatory T cell-based therapeutics are designed to mimic the function of naturally occurring Type 1 regulatory T (Tr1) cells, an important subset of regulatory cells. Our products work to restore immune tolerance, stopping severe autoimmune and inflammatory diseases in their tracks.

The Science

An approach to cellular therapies for immune diseases that scales.

Blue shape

We are combining the latest advances in genetic engineering with decades of T cell biology research to develop scalable, effective cellular therapies targeting inflammation and autoimmunity.

Our Programs

Targeted & Localized Immune Suppression


Blue shape

Our cells produce suppressive cytokines in local microenvironments, while preserving protective immune responses.


High Stability, Low Plasticity


Blue shape

Our cells are stable and long lived, even in inflammatory environments.


Induction of De-novo Tregs


Blue shape

Our cells migrate to sites of inflammation, modulating effector cell responses and inducing de-novo Tr1 cells.



Relentlessly dedicated to improving the lives of patients.

We are pursuing breakthrough innovation in the spaces of autoimmunity and inflammation with a world-class team aiming to change the way devastating diseases are treated.

Our Team


Passion Driven,
Mission Focused.

We strive to create a collaborative, diverse environment to bring the best out of one another. We are committed to our goals, and to one another, while making sure we enjoy the journey as much as the destination.

View Open Positions
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.